Last edition
News about "Idiopathic Pulmonary Fibrosis"
Transpire Bio Secures FDA Filing Acceptance for Generic High-Strength Trelegy Ellipta ANDA
Transpire Bio receives US Food and Drug Administration (FDA) filing acceptance for its generic high-strength Trelegy Ellipta ANDA with Paragraph IV certification under the Hatch-Waxman Act.
Idiopathic Pulmonary Fibrosis | 12/05/2026 | By News Bureau
Addex Therapeutics Reports Promising Preclinical Results for Novel Chronic Cough Therapy
Addex Therapeutics’ experimental GABAB modulator shows potential as a well-tolerated, long-term treatment option for chronic cough, addressing a significant unmet need in idiopathic pulmonary fibrosis patients.
Idiopathic Pulmonary Fibrosis | 04/05/2026 | By News Bureau
Cipla USA Secures USFDA Approval for Generic Nintedanib to Treat Pulmonary Fibrosis
Cipla USA receives USFDA approval for generic Nintedanib capsules, expanding access to treatment for patients with idiopathic pulmonary fibrosis in the United States.
Idiopathic Pulmonary Fibrosis | 06/04/2026 | By News Bureau | 232
ArkBio Receives US FDA IND Clearance for AK3280 in Idiopathic Pulmonary Fibrosis
FDA clears ArkBio’s IND application for AK3280, enabling a Phase II proof-of-concept trial in the US to evaluate the novel anti-fibrotic therapy in patients with idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis | 12/02/2026 | By News Bureau | 123
Remedy Cell Launches Phase 1b Trial of RC-0315 in IPF
First-in-human study evaluates safety and tolerability of intra-bronchial RC-0315, a cell-derived therapy aimed at reducing fibrosis and restoring lung function in idiopathic pulmonary fibrosis patients.
Idiopathic Pulmonary Fibrosis | 08/01/2026 | By News Bureau | 170
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy